Enhancing psychiatric care with pharmacogenomics (PGx)

With more than 25 years of nursing experience, Josh Hamilton holds professorial appointments, academic leadership positions and provides extensive professional consultation services in higher education, industry and clinical affairs. He was associate medical director for the largest managed care behavioral health network in the Desert Southwest and, as a university dean and vice president, he built one of the largest portfolio collections of competency-based graduate Nursing degrees in the United States. He is a NEI Master Psychopharmacologist and a fellow of the American Association of Nurse Practitioners. The Point of Care Network proclaimed Josh to be America’s Top Psychiatric NP in 2021.

 LinkedIn

Dr. Ali, a double board-certified psychiatrist in child, adolescent, and adult psychiatry, specializes in complex neuropsychiatric disorders. As Senior Director of Medical Affairs at Tempus AI's neuropsychiatry division, he educates providers on precision medicine and pharmacogenomics, aiming to enhance the field with AI and machine learning tools. Clinically, he adopts a holistic approach, focusing on relationship dynamics and treating ADHD, anxiety, and substance use disorders. Dr. Ali trained at the State University of New York, where he completed a fellowship and served as Chief Fellow in Child and Adolescent Psychiatry. He holds board certifications through the American Board of Psychiatry and Neurology.

 LinkedIn

Dr. Mothaffar Rimawi is a board-certified oncologist with additional training in breast cancer clinical care and translational research. He is the Associate Director for Clinical Affairs and Executive Medical Director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine and Baylor St Luke’s Medical Center. He is a funded investigator focused on translation of preclinical discoveries to the clinic by designing and conducting biologically rational, biospecimen-intense targeted therapy clinical trials. Dr. Rimawi studies biomarkers of response and resistance on tumor samples from these trials samples to help elucidate mechanisms of therapeutic resistance. His overall research focus is on precision medicine approaches to breast cancer patients and developing a treatment de-escalation strategy to spare cancer patients the unnecessary toxicity and cost, when possible, without compromising outcomes. His work helped advance dual HER2 inhibition, concurrent targeting of ER with HER2, better understanding of endocrine therapy resistance, and treatment de-escalation in HER2-positive breast cancer. Dr. Rimawi serves on multiple national clinical research leadership committees. He is Vice Chair of the Breast Committee of the NRG Oncology Group, and co-Chair the HER2 Working group of the Translational Breast Cancer Symposium (TBCRC).

Dr. Ezra Cohen is a leading medical oncologist and cancer researcher who brings a unique combination of extensive clinical and research experience to Tempus’ leadership team. He was most recently the Chief of the Division of Hematology-Oncology as well as the Associate Director of Clinical Science at UC San Diego (UCSD) Moores Cancer Center. Dr. Cohen also led the Precision Immunotherapy Clinic and co-directed the San Diego Center for Precision Immunotherapy at UCSD. Before UCSD, Dr. Cohen spent 15 years at the University of Chicago, where he was the co-director of the Head and Neck Cancer Program as well as Hematology/Oncology Fellowship Program Director.